BACK

FRα ADC

CompoundAZD5335

Area under investigation

Advanced solid tumors, NSCLC, Ovarian cancer

Scientific PillarAntibody-Drug Conjugates

Target Overview

FRα is a high-affinity receptor for folates with restricted expression in normal tissue and overexpression in many solid tumors (eg, ovarian and lung adenocarcinoma). Supporting the high demand of cancer cells for folate to increase metabolism and proliferation is its main function.1

Compound Overview

AZD5335 is a FRalpha-targeting antibody-drug conjugate conjugated to topoisomerase 1 inhibitor (TOP1) payload with potential bystander antitumor activity. Upon internalization and trafficking to the lysosome, the TOP1i payload is released. Binds and traps topoisomerase 1 on DNA and eventually causes cell death.2

Mechanism of Action

  • Mechanism of Action

References

1. Scaranti M, Cojocaru E, Banerjee S, Banerji U. Nat Rev Clin Oncol. 2020;17(6):349-359. 2. Pommier Y. ACS Chem Biol. 2013;8:82-95.

Clinical trial information


Select trial for more information

Arrange By

Abbreviations

View full glossary

  • DNA

    deoxyribonucleic acid

  • FRα

    folate receptor α

  • TOP1i

    topoisomerase 1 inhibitor

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-80919 US-109129 DE-92568 Last Updated April 20263/26
©2026 AstraZeneca. All rights reserved.